$MRNA 24 hours down nearly 4.6%, funding rate -0.00005. Two signals point in the same direction: the market is betting it cannot withstand geopolitical uncertainty.
When political and military events escalate, capital first abandons high-valuation growth stocks that rely on global supply chains. Moderna's mRNA technology platform is strong, but if global public health cooperation is hindered by conflict, the uncertainty around R&D pipeline progress and order execution will increase. A negative funding rate means shorts are paying longs; shorts are relatively crowded, but the price keeps falling, indicating that selling pressure is heavier than the money shorts are paying. This is not a balance between bulls and bears; it is a one-sided structure dominated by shorts.
Open interest of 9364 is not extreme, but open interest during a decline means either new short positions are being opened or existing longs are stubbornly holding on. If the price rebounds here, the negative funding rate could enlarge short losses and possibly trigger a brief short squeeze. But the core logic has not changed: before geopolitical risk is resolved, the market will choose to de-risk first on this kind of biotech stock that depends on international cooperation.
My view is bearish. But if the price can reclaim 148 on volume and the funding rate quickly turns positive, that would mean the risk-off sentiment has been offset by other factors, and this short thesis would fail.
For now, the plan is to wait for a rebound test around 146 and lightly short, with a stop loss at 148.5.
Trade tag: #TradFi #链上美股 #MRNA
Where do you think this line of reasoning is most likely to be wrong?
When political and military events escalate, capital first abandons high-valuation growth stocks that rely on global supply chains. Moderna's mRNA technology platform is strong, but if global public health cooperation is hindered by conflict, the uncertainty around R&D pipeline progress and order execution will increase. A negative funding rate means shorts are paying longs; shorts are relatively crowded, but the price keeps falling, indicating that selling pressure is heavier than the money shorts are paying. This is not a balance between bulls and bears; it is a one-sided structure dominated by shorts.
Open interest of 9364 is not extreme, but open interest during a decline means either new short positions are being opened or existing longs are stubbornly holding on. If the price rebounds here, the negative funding rate could enlarge short losses and possibly trigger a brief short squeeze. But the core logic has not changed: before geopolitical risk is resolved, the market will choose to de-risk first on this kind of biotech stock that depends on international cooperation.
My view is bearish. But if the price can reclaim 148 on volume and the funding rate quickly turns positive, that would mean the risk-off sentiment has been offset by other factors, and this short thesis would fail.
For now, the plan is to wait for a rebound test around 146 and lightly short, with a stop loss at 148.5.
Trade tag: #TradFi #链上美股 #MRNA
Where do you think this line of reasoning is most likely to be wrong?